Business
FY 2025 Trading Update
EKF Diagnostics Holdings plc reported a strong FY 2025, with revenues increasing 3% to £51.6 million and gross margins improving to 51%, driven by growth in Point-of-Care and Life Sciences divisions. Adjusted EBITDA is projected to rise nearly 10% to £12.4 million, in line with forecasts, and cash reserves grew to £15.8 million as of December 31, 2025, with no bank borrowings. The company also continued its share buy-back program, purchasing shares at an average price of 25.13 pence. Disclaimer*
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n\n \n\n \nEKF Diagnostics Holdings plc\n(\"EKF\" or the \"Company\")\n \nFY 2025 Trading Update\n \nStrong foundation for five-year growth strategy\nAdjusted EBITDA up c. 10%\n \nEKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, provides a trading update for the year ended 31 December 2025 (\"FY 2025\").\n \nFY 2025 was a period that has provided a strong foundation for the five-year strategy plan focussing on:\n \n· becoming #1 in global Point-of-Care (POC) Hematology testing\n· cementing EKF's leading position in β-HB supply\n· accelerating the transformation of the Life Sciences division into a world class Contract Development and Manufacturing Organisation (CDMO)\n \nFY 2025 revenues were up 3% to £51.6m (FY 2024: £50.2m), reflecting the continued focus on higher margin product ranges and core operations, and the winding down of non-core and low margin product lines and services.\n \nPOC revenues (Hematology and Diabetes) increased by 6.5% and Life Sciences (β-HB and Fermentation) grew by 7.2%. β-HB sales improved by 10% and a new fermentation development agreement was signed with a significant diagnostic customer which has contributed additional revenues towards the end of 2025, with this continuing into 2026; as well as further potential sales ramp up as product is considered for onshore development within the US.\n \nGross margins continued to improve and stood at 51% for the period (FY 2024: 48%) and adjusted EBITDA1, subject to completion of the audit, is expected to be up nearly 10% to £12.4m2 (FY 2024: £11.3m), in-line with consensus forecasts.\n \nCash generation continues to be strong. Cash as at 31 December 2025 was £15.8m (Cash at 31 December 2024: £14.3m), after the deployment in 2025 of £5.1m of on-market purchases in the share buy-back programme and investment for growth that is part of the five-year strategic development plan. Cash balances in Russia which are included FY 2025 figure were £2.1m (£1.3m as at 31 December 2024). The Company has no bank borrowings.\n \nUpdate on share buy-back programme\nSince the commencement of the current programme, the Company has purchased a total of 21,150,452 ordinary shares of 1p each in the capital of the Company (\"Or...